Durvalumab Becomes First Immunotherapy Approved for Stage III Lung Cancer
Durvalumab Becomes First Immunotherapy Approved for Stage III Lung Cancer
From the Cancer Research Institute website:
https://www.cancerresearch.org/blog/february-2018/durvalumab-stage-iii-lung-cancer-fda-approval
On Friday, February 16, 2018, the FDA approved durvalumab (IMFINZI ®, AstraZeneca), an anti-PD-L1 checkpoint immunotherapy, for patients with unresectable, stage III non-small cell lung cancer (NSCLC) that hasn’t progressed after prior chemo-radiation treatment. Importantly, this approval covers patients regardless of their PD-L1 expression status.
